High TMB and MSI-high as independent predictors of survival in NENs

#3250

Introduction: To date, there are no validated molecular biomarkers for personalized therapy in NENs. Tumor genome sequencing may help unravel NEN molecular landscape and identify novel targets for an individualized approach.

Aim(s): We report tumor mutational burden (TMB) and microsatellite instability (MSI) status, two novel tumor-agnostic biomarkers with potential prognostic/therapeutic implications, in a cohort of 31 metastatic NENs.

Materials and methods: We conducted molecular profiling through comprehensive tumor exome sequencing by the FoundationOne CDx test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: La Salvia A, Barroso G, Espinosa Olarte P, Anton Pascual B, Modrego Sanchez A,

Keywords: molecular profiling, neuroendocrine neoplasm, TMB, microsatellite instability (MSI)/mismatch repair deficiency (MMRd) status, prognosis,